日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.

接受奥瑞珠单抗和其他疾病修饰疗法治疗的多发性硬化症患者的 SARS-CoV-2 感染的细胞和体液免疫:一项多民族观察性研究

Kister Ilya, Patskovsky Yury, Curtin Ryan, Pei Jinglan, Perdomo Katherine, Rimler Zoe, Voloshyna Iryna, Samanovic Marie I, Cornelius Amber R, Velmurugu Yogambigai, Nyovanie Samantha, Kim Joseph J, Tardio Ethan, Bacon Tamar E, Zhovtis Ryerson Lana, Raut Pranil, Pedotti Rosetta, Hawker Kathleen, Raposo Catarina, Priest Jessica, Cabatingan Mark, Winger Ryan C, Mulligan Mark J, Krogsgaard Michelle, Silverman Gregg J

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS)

一项为期一年的前瞻性、随机、安慰剂对照、四盲、II期安全性试点试验,研究干扰素β-1a和吗替麦考酚酯联合疗法治疗早期复发缓解型多发性硬化症的疗效(TIME MS)。

Remington, Gina M; Treadaway, Katherine; Frohman, Teresa; Salter, Amber; Stüve, Olaf; Racke, Michael K; Hawker, Kathleen; Agosta, Federica; Sormani, Maria Pia; Filippi, Massimo; Frohman, Elliot M

B cells as a target of immune modulation

B细胞作为免疫调节的靶点

Hawker, Kathleen

Genetic analysis of the exon 1 position 49 CD152 dimorphism in multiple sclerosis

多发性硬化症中 CD152 外显子 1 第 49 位二态性的遗传分析

Stuart, Rodney; Lovett-Racke, Amy E; Frohman, Elliot M; Hawker, Kathleen; Racke, Michael K